









Markets
/
Stocks
/
nasdaq-carm
/

Carisma Therapeutics Inc

CARM

View Detailed Chart

0.303USD

-0.009-2.76%

Market hours （ET）Quotes delayed by 15 min

12.66MMarket Cap

LossP/E TTM



Carisma Therapeutics Inc

0.303

-0.009-2.76%

Overview Company Financials

Financials

Intraday

30m

Today

-2.76%

5 Days

-21.93%

1 Month

-24.84%

6 Months

-33.72%

Year to Date

-27.67%

1 Year

-68.94%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 2 analysts

BUY

Current Rating

1.000

Target Price

221.03%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Carisma Therapeutics Inc

CARM

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(9)

Neutral(1)

Buy(0)

Indicators

Sell(3)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.024

Sell

RSI(14)

38.092

Neutral

STOCH(KDJ)(9,3,3)

14.894

Oversold

ATR(14)

0.032

Low Volatility

CCI(14)

-157.421

Sell

Williams %R

90.644

Oversold

TRIX(12,20)

-0.516

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.335

Sell

MA10

0.363

Sell

MA20

0.384

Sell

MA50

0.368

Sell

MA100

0.314

Sell

MA200

0.482

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.

Ticker SymbolCARM

CompanyCarisma Therapeutics Inc

CEOMr. Steven (Steve) Kelly

Websitehttps://sesenbio.com/